In the published article, there was an error in Figure 8 as published. The results of a mistaken measurement were shown in Figures 8A, B. Consequently, the numerical values of the t-test comparing the phospho-tau/total tau ratios in the control and STZ treated groups in EXP1 and EXP2 are inadequate. The corrected Figure 8 and its corrected caption appear below:
FIGURE 8
The effect of icv. STZ or citrate buffer (control) treatment on the tissue protein levels of phospho-Tau (A,B) and β-amyloid (C,D) in EXP1 (A,C) and EXP2 (B,D) measured by Western blot. Means ± SEM values are shown. There was no significant difference between the groups in phospho-tau/tau ratio in EXP1 (unpaired t-test: t (14) = −0.19, ns) (A) whereas a trend for an increase in the STZ group can be seen in EXP2 (unpaired t-test: t (22) = −2.012, p = 0.06) (B) Also, there was no significant difference in β-amyloid level in EXP1 (unpaired t-test: t (13) = −1.13, ns) (C) while significantly elevated β-amyloid level was found in the STZ-treated group in EXP2 (unpaired t-test: t (20) = −2.45, p < 0.05 (D) *<0.05, #<0.10.
Furthermore, the name and catalogue number of the phospho-tau antibody in the Western Blot section was erroneous. As such, a correction has been made to “Methods and materials, Western Blot.” The sentence previously stated:
“Membranes were incubated with primary antibodies against PHF1 (sc515013, 1:1,000, Santa Cruz Biotechnology, Santa Cruz, CA, United States)…”
The corrected sentence appears below:
“Membranes were incubated with primary antibodies against PHF-13 (sc32275, 1:1,000, Santa Cruz Biotechnology, Santa Cruz, CA, United States)…”
The numerical values of the multivariate analysis of variance results were also inadequate. Therefore, a correction has been made to “Results, Multivariate analysis of variance.” The sentence previously stated:
“The difference between the control and STZ groups was significant in EXP2 (Wilks λ = 0.391, F(4,13) = 5.054; p = 0.011) whereas it was not significant in EXP1 (Wilks λ = 0.750, F(4,7) = 0.583; p = 0.685298344).”
The corrected sentence appears below:
“The difference between the control and STZ groups was significant in EXP2 (Wilks λ = 0.397, F(4,13) = 4,931; p = 0.012) whereas it was not significant in EXP1 (Wilks λ = 0.583, F(4,6) = 1.072; p = 0.446).”
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated. This is a provisional file, not the final typeset article
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
Alzheimer disease model, STZ icv., cognitive test battery, learning impairment, β-amyloid, phospho-tau
Citation
Gáspár A, Hutka B, Ernyey AJ, Tajti BT, Varga BT, Zádori ZS and Gyertyán I (2023) Corrigendum: Intracerebroventricularly Injected Streptozotocin Exerts Subtle Effects on the Cognitive Performance of Long-Evans Rats. Front. Pharmacol. 13:1122260. doi: 10.3389/fphar.2022.1122260
Received
12 December 2022
Accepted
16 December 2022
Published
05 January 2023
Volume
13 - 2022
Edited and reviewed by
Arjan Blokland, Maastricht University, Netherlands
Updates
Copyright
© 2023 Gáspár, Hutka, Ernyey, Tajti, Varga, Zádori and Gyertyán.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: István Gyertyán, gyertyan.istvan@med.semmelweis-univ.hu
This article was submitted to Neuropharmacology, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.